PMID- 23393027
OWN - NLM
STAT- MEDLINE
DCOM- 20130906
LR  - 20220408
IS  - 1869-1889 (Electronic)
IS  - 1674-7305 (Linking)
VI  - 56
IP  - 2
DP  - 2013 Feb
TI  - Studies on abacavir-induced hypersensitivity reaction: a successful example of 
      translation of pharmacogenetics to personalized medicine.
PG  - 119-24
LID - 10.1007/s11427-013-4438-8 [doi]
AB  - Abacavir is an effective nucleoside analog reverse transcriptase inhibitor used 
      to treat human immunodeficiency virus (HIV) infected patients. Its main side 
      effect is hypersensitivity reaction (HSR). The incidence of the HSR is associated 
      with ethnicity among patients exposed to abacavir, and retrospective and 
      prospective studies show a significantly increased risk of abacavir-induced HSR 
      in human leukocyte antigen (HLA)-B*57:01-carrying patients. Immunological studies 
      indicated that abacavir interacts specifically with HLA-B*57:01 and changed the 
      binding specificity between the HLA molecule and the HLA-presented endogenous 
      peptide repertoire, leading to a systemic autoimmune reaction. HLA-B*57:01 
      screening, combined with patch testing, had clinically predictive value and 
      cost-effective impact in reducing the incidence of abacavir-induced HSR 
      regardless of the HLA-B*57:01 prevalence in the population. Therefore, the US 
      Food and Drug Administration (FDA) and international HIV treatment guidelines 
      recommend a routine HLA-B*57:01 screening prior to abacavir treatment to decrease 
      false positive diagnosis and prevent abacavir-induced HSR. The studies of 
      abacavir-induced HSR and the implementation of the HLA-B*57:01 screening in the 
      clinic represent a successful example of the use of pharmacogenetics for 
      personalized diagnosis and therapy.
FAU - Guo, Yongli
AU  - Guo Y
AD  - Division of Systems Biology, National Center for Toxicological Research, the US 
      Food and Drug Administration, Jefferson, AR 72079, USA.
FAU - Shi, Leming
AU  - Shi L
FAU - Hong, Huixiao
AU  - Hong H
FAU - Su, Zhenqiang
AU  - Su Z
FAU - Fuscoe, James
AU  - Fuscoe J
FAU - Ning, Baitang
AU  - Ning B
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130208
PL  - China
TA  - Sci China Life Sci
JT  - Science China. Life sciences
JID - 101529880
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Dideoxynucleosides)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-B*57:01 antigen)
RN  - WR2TIP26VS (abacavir)
SB  - IM
EIN - Sci China Life Sci. 2013 Mar;56(3):292
MH  - Anti-HIV Agents/*adverse effects
MH  - Dideoxynucleosides/*adverse effects
MH  - Drug Hypersensitivity/*genetics/immunology/prevention & control
MH  - Gene Frequency
MH  - Genetic Testing
MH  - HIV Infections/drug therapy/genetics/immunology
MH  - HLA-B Antigens/genetics
MH  - Histocompatibility Testing
MH  - Humans
MH  - Pharmacogenetics/methods
MH  - Precision Medicine/methods
MH  - Translational Research, Biomedical/methods
EDAT- 2013/02/09 06:00
MHDA- 2013/09/07 06:00
CRDT- 2013/02/09 06:00
PHST- 2012/12/11 00:00 [received]
PHST- 2012/12/22 00:00 [accepted]
PHST- 2013/02/09 06:00 [entrez]
PHST- 2013/02/09 06:00 [pubmed]
PHST- 2013/09/07 06:00 [medline]
AID - 10.1007/s11427-013-4438-8 [doi]
PST - ppublish
SO  - Sci China Life Sci. 2013 Feb;56(2):119-24. doi: 10.1007/s11427-013-4438-8. Epub 
      2013 Feb 8.